MissionIR Articles
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Reports Q1 Milestones for Subsidiary — Notes Corrected Information
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on psychedelic pharmaceutical therapies, has noted key achievements reached by its wholly owned subsidiary Adelia Therapeutics Inc. Most notably, Adelia has achieved key milestones outlined in…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Begin Trading on NYSE American
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that on trading opens on Aug. 5, 2021, its common shares will be trading on the NYSE American LLC stock…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Receives Listing Approval from NYSE American
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has received approval for its common shares to trade on the NYSE American LLC stock exchange. According to the announcement, the company…
-
Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Files Patent, Adds New Dimension to Development Strategy
Digital therapeutics platform is proprietary to Cybin and the subject of the company’s 13th patent application Company focused on utilizing, leveraging cutting-edge technologies to support drug-development candidates Cybin is confident this added focus will better enable…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Receives Listing Approval from NYSE American
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, will be moving exchanges. The company has announced that it received conditional listing approval from the NYSE American LLC stock exchange. The…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Moving Psychedelic Therapeutics Field Forward Through Partnership
Cybin (NEO: CYBN) (OTCQB: CLXPF), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, is sponsoring research to see if psychedelic medicine, when used with EMBARK’s supportive therapy, can help clinicians…
-
Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces New Board Appointment
Former head of psychiatry products at FDA joins Cybin team. Laughren will help company plot its regulatory pathway as it studies and develops psychedelic medicines. Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on…
-
Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Acquisition Leads to Milestone Achievement, Positive Pre-Clinical Results
CYBN subsidiary Adelia Therapeutics has reached earn-out milestones. Adelia’s earn-out milestones contributed to positive preclinical results with multiple proprietary psychedelic molecules. Cybin’s development of these compounds differentiates it from companies focused on naturally occurring psychedelic…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Files Patent as Part of Digital Therapeutics Strategy
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has filed a new provisional patent application to protect its proprietary digital therapeutics platform; the patent is the company’s 13th. In addition,…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Notes European Expansion, IP Portfolio Updates, to Participate in Neuropsychiatry Virtual Summit
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, is increasing its focus and research activities in Europe. The company announced that it is working with several academic and clinical research…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces Agreement with US Mental Health Chain Group
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has entered into an exclusive research and development collaboration agreement with TMS NeuroHealth Centers Inc. (“TMS”). TMS is a wholly owned subsidiary…
-
Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Featured in Stifel Report; Price Target Raised by C$12, Rated as Spec Buy
CYBN continues to demonstrate good progress with its preclinical activities on its novel drug programs, report observed Stifel also notes selecting indications with large patient pools, an understated market size, and potential for multiple synergies…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces Annual Financial Results, Business Highlights and Adelia Milestones
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today released financial and business highlights for its financial year ended March 31, 2021. “It has been an incredibly busy and successful…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Participate in Fireside Chat at Grizzle Psychedelics Con
Cybin (NEO: CYBN) (OTCQB: CLXPF) is a leading biotechnology company focused on progressing psychedelic therapeutics. The company has announced that its Chief Executive Officer Doug Drysdale will participate in a virtual fireside chat at Grizzle…
-
Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Targets Anxiety Disorders in Focus of Proprietary Psychedelic Treatments
Decision represents opportunity to help millions suffering from social, generalized anxiety disorders Global markets will reach an estimated $4 billion this year, with significant growth projected looking forward WHO estimates that 1 in 13 adults…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Names Former FDA Psychiatry Division Director to Clinical Advisory Board
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, announced its newest Clinical Advisory Board member: Dr. Thomas Laughren. A former director for the Division of Psychiatry Products, Center for Drug…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces Participation at Life Sciences Investor Forum
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, will be participating in the upcoming Life Sciences Investor Forum, scheduled for June 24, 2021. During the presentation, Cybin’s CEO Doug Drysdale…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Completes 51st Pre-Clinical Psychedelic Molecule Study
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, announced that it has completed its 51st preclinical study; the study is a critical step in the company’s progress in the Investigational…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Participate at the Emerging Growth Conference
Cybin (NEO: CYBN) (OTCQB: CLXPF) has announced that its CEO Doug Drysdale will be participating at the 2021 Emerging Growth Conference, which is scheduled for June 23, 2021.As part of his participation, Drysdale will be…
-
Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces First-Ever Trial to Treat COVID-19 Frontline Clinicians, Unveils EMBARK Model
The study will examine treating symptoms of depression, anxiety, burnout and post-traumatic stress EMBARK is groundbreaking psychotherapy model that integrates leading clinical approaches to promote supportive healing with psychedelic medicine Cybin considers it an honor,…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Marks Pivotal Moment on Path to 2026 Rare Earth Oxide Production
- PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) Marks Bold Entry Into the Growing Battery Storage Market with 4.99 MW BESS in Ontario
- Soligenix Inc. (NASDAQ: SNGX) Working to Advance Heat-Stable Ricin Vaccine with Promising Efficacy
- New Pacific Metals Corp. (NYSE American: NEWP) (TSX: NUAG) Eyes Bolivia’s Untapped Silver Potential Amid Global Supply Gaps
- MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q2 2025 Results, Advances TPI 287 Toward Phase 2 GBM Trial